Higuero Sevilla JP, Memon A, Hinchcliff M. Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease. Arthritis Res Ther. 2023;25(1):118.

Article  PubMed  PubMed Central  Google Scholar 

Shappley C, Paik JJ, Saketkoo LA. Myositis-Related interstitial lung diseases: diagnostic features, treatment, and complications. Curr Treat Options Rheumatol. 2019;5(1):56–83.

Article  Google Scholar 

Basuita M, Fidler LM. Myositis antibodies and interstitial lung disease. J Appl Lab Med. 2022;7(1):240–58.

Article  PubMed  Google Scholar 

Hallowell RW, Danoff SK. Diagnosis and management of Myositis-Associated lung disease. Chest. 2023;163(6):1476–91.

Article  CAS  PubMed  Google Scholar 

Tzilas V, Ryu JH, Sfikakis PP, Tzouvelekis A, Bouros D. Antisynthetase syndrome with predominant lung involvement. An easy to miss diagnosis. Pulmonology. 2023;29(4):271–2.

Article  CAS  PubMed  Google Scholar 

Zamora AC, Hoskote SS, Abascal-Bolado B, White D, Cox CW, Ryu JH, et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. Respir Med. 2016;118:39–45.

Article  PubMed  Google Scholar 

Tzilas V, Tzouvelekis A, Sotiropoulou V, Panopoulos S, Bouros E, Avdoula E, et al. Presenting clinical and imaging features of patients with clinically amyopathic interstitial lung disease associated with myositis-specific autoantibodies. Front Med. 2024;11:1392659.

Article  Google Scholar 

Cavagna L, Trallero-Araguás E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E et al. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J Clin Med. 2019;8(11).

Tzilas V, Sfikakis PP, Bouros D. Antisynthetase syndrome masquerading as hypersensitivity pneumonitis. Respir Int Rev Thorac Dis. 2021;100(11):1105–13.

CAS  Google Scholar 

Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, et al. 2023 American college of rheumatology (ACR)/American college of chest physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Care Res. 2024;76(8):1051–69.

Article  Google Scholar 

Barba T, Fort R, Cottin V, Provencher S, Durieu I, Jardel S, et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis. Autoimmun Rev. 2019;18(2):113–22.

Article  PubMed  Google Scholar 

Lombardi F, Stewart I, Fabbri L, Adams W, Kawano-Dourado L, Ryerson CJ et al. Mycophenolate and azathioprine efficacy in interstitial lung disease: a systematic review and meta-analysis. BMJ Open Respir Res. 2024;11(1).

Huapaya JA, Silhan L, Pinal-Fernandez I, Casal-Dominguez M, Johnson C, Albayda J, et al. Long-Term treatment with azathioprine and mycophenolate mofetil for Myositis-Related interstitial lung disease. Chest. 2019;156(5):896–906.

Article  PubMed  PubMed Central  Google Scholar 

Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue Disease-associated interstitial. Lung Disease. 2013;40(5):640–6.

CAS  Google Scholar 

Boerner EB, Cuyas M, Theegarten D, Ohshimo S, Costabel U, Bonella F. Azathioprine for connective tissue disease-Associated interstitial lung disease. Respiration. 2020;99(8):628–36.

Article  CAS  PubMed  Google Scholar 

Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007;46(1):124–30.

Article  CAS  PubMed  Google Scholar 

Moreno-Torres V, Martín-Iglesias D, Vivero F, González-Echavarri C, García-Moyano M, Enghelmayer JI, et al. Intravenous cyclophosphamide improves functional outcomes in interstitial lung disease related to idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2023;59:152164.

Article  CAS  PubMed  Google Scholar 

Ge Y, Peng Q, Zhang S, Zhou H, Lu X, Wang G. Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clin Rheumatol. 2015;34(1):99–105.

Article  PubMed  Google Scholar 

Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with High-Dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by Anti-Melanoma Differentiation-Associated gene 5-Positive dermatomyositis. Arthritis Rheumatol. 2020;72(3):488–98.

Article  CAS  PubMed  Google Scholar 

You H, Lv C, Xu L, Wang L, Liu T, Yuan F, et al. Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study. Clin Exp Rheumatol. 2025;43(2):251–9.

PubMed  Google Scholar 

Abdi M, Fadaee M, Jourabchi A, Karimzadeh H, Kazemi T. Cyclophosphamide-Induced infertility and the impact of antioxidants. Am J Reprod Immunol. 2024;92(6):e70014.

Article  CAS  PubMed  Google Scholar 

Fujisawa T. Management of Myositis-Associated interstitial lung disease. Med (Kaunas). 2021;57(4).

Liossis SC, Bounia CA. Treating Autoimmune-Related interstitial lung disease with B cell depletion. Front Med (Lausanne). 2022;9:937561.

Article  PubMed  Google Scholar 

Bauhammer J, Blank N, Max R, Lorenz HM, Wagner U, Krause D, et al. Rituximab in the treatment of Jo1 Antibody-associated antisynthetase syndrome: Anti-Ro52 positivity as a marker for severity and treatment response. J Rhuematol. 2016;43(8):1566–74.

Article  CAS  Google Scholar 

Conticini E, Cameli P, Grazzini S, d’Alessandro M, Bergantini L, Porcelli B, et al. Efficacy and safety of a step-down regimen of low dosage of glucocorticoids combined with early administration of synthetic or biologic immunosuppressants in anti-synthetase syndrome: A pilot study. Semin Arthritis Rheum. 2024;69:152560.

Article  CAS  PubMed  Google Scholar 

Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, et al. Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase Auto-Antibodies: an Open-Label, phase II trial. PLoS ONE. 2015;10(11):e0133702.

Article  PubMed  PubMed Central  Google Scholar 

Narváez J, Cañadillas E, Castellví I, Alegre JJ, Vicens-Zygmunt V, Bermudo G, et al. Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome. Arthritis Res Ther. 2024;26(1):122.

Article  PubMed  PubMed Central  Google Scholar 

Langlois V, Gillibert A, Uzunhan Y, Chabi ML, Hachulla E, Landon-Cardinal O, et al. Rituximab and cyclophosphamide in antisynthetase Syndrome-related interstitial lung disease: an observational retrospective study. J Rhuematol. 2020;47(11):1678–86.

Article  CAS  Google Scholar 

Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023;11(1):45–54.

Article  CAS  PubMed  Google Scholar 

Mankikian J, Caille A, Reynaud-Gaubert M, Agier MS, Bermudez J, Bonniaud P et al. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J. 2023;61(6).

Mansy L, Caille A, Reynaud-Gaubert M, Bermudez J, Bonniaud P, Borie R et al. Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial. Eur Respir J. 2024;64(3).

He C, Li W, Xie Q, Yin G. Rituximab in the treatment of interstitial lung diseases related to Anti-Melanoma Differentiation-Associated gene 5 dermatomyositis: A systematic review. Front Immunol. 2021;12:820163.

Article  CAS  PubMed  Google Scholar 

Efe O, Sauvage G, Chung J, Jeyabalan A, Al Jurdi A, Seethapathy HS, et al. Protracted COVID-19 pneumonia in B-cell-depleted patients. Rheumatology. 2024;64(4):2303–5.

Article  PubMed Central  Google Scholar 

Lee H, Myoung H, Kim SM. Review of two immunosuppressants: tacrolimus and cyclosporine. J Korean Assoc Oral Maxillofac Surg. 2023;49(6):311–23.

Article  PubMed  PubMed Central  Google Scholar 

Ge Y, Zhou H, Shi J, Ye B, Peng Q, Lu X, et al. The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. Clin Rheumatol. 2015;34(12):2097–103.

Article  PubMed  Google Scholar 

Sasai T, Nakashima R, Tsuji H, Nakajima T, Imura Y, Yoshida Y, et al. Long-Term prognosis of antimelanoma Differentiation-Associated gene 5-Positive dermatomyositis with interstitial lung disease. J Rheumatol. 2023;50(11):1454–61.

Article  CAS  PubMed  Google Scholar 

Fujisawa T, Hozumi H, Kamiya Y, Kaida Y, Akamatsu T, Kusagaya H, et al. Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: A randomized, open-label trial. Respirology. 2021;26(4):370–7.

Article  PubMed